HRP20160404T1 - Metoda za proizvodnju trombocita - Google Patents

Metoda za proizvodnju trombocita Download PDF

Info

Publication number
HRP20160404T1
HRP20160404T1 HRP20160404TT HRP20160404T HRP20160404T1 HR P20160404 T1 HRP20160404 T1 HR P20160404T1 HR P20160404T T HRP20160404T T HR P20160404TT HR P20160404 T HRP20160404 T HR P20160404T HR P20160404 T1 HRP20160404 T1 HR P20160404T1
Authority
HR
Croatia
Prior art keywords
vwf
fragment
mature
variant
von willebrand
Prior art date
Application number
HRP20160404TT
Other languages
English (en)
Inventor
Dominique Baruch
Elisabeth Cramer-Borde
Claire Dunois-Larde
Original Assignee
INSERM (Institut National de la Santé et de la Recherche Médicale)
Assistance Publique HĂ´pitaux De Paris
Universite Paris Descartes
L'universite De Versailles Saint Quentin En Yvelines
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Assistance Publique Hôpitaux De Paris, Universite Paris Descartes, L'universite De Versailles Saint Quentin En Yvelines filed Critical INSERM (Institut National de la Santé et de la Recherche Médicale)
Publication of HRP20160404T1 publication Critical patent/HRP20160404T1/hr
Publication of HRP20160404T8 publication Critical patent/HRP20160404T8/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins

Claims (5)

1. Ex vivo metoda za proizvodnju trombocita, obuhvaća korak podvrgavanja suspenzije zrelih megakariocita protoku dozvoljavajući izlaganje naprezanju odgovarajućem za stvaranje trombocita i na čvrstoj fazi oblaganje Von Willebrandovim faktorom (VWF), ili njegovim fragmentom ili inačicom ili analogom, koji veže GPlb.
2. Metoda u skladu s patentnim zahtjevom 1, pri čemu je navedeni fragment ili inačica ili analog VWF odabran iz grupe koja se sastoji od triptičkog fragmenta VWF od 52/48-kDa; Staphylococcus aureus V-8 proteazom razgrađenog VWF; koncentrata VWF za terapijsku uporabu i VWF mutanata odgovornih za tip 2N von Willebrandove bolesti.
3. Metoda u skladu s patentnim zahtjevom 1 ili 2, pri čemu su navedeni zreli megakariociti izloženi naprezanju veličine od barem 1000 s-1.
4. Metoda u skladu s patentnim zahtjevom 1, pri čemu je koncentracija navedenih stanica u kulturi sadržana između 0.5 i 4 x 106/mL ili je najmanje 4 x 106/mL.
5. Metoda za promicanje oblikovanja trombocita, obuhvaća zrele megariocite u uvjetima protoka u prisutnosti sila naprezanja u protočnoj komori pri čemu protočna komora ima donju stijenku obloženu s VWF.
HRP20160404TT 2008-12-04 2016-04-18 Metoda za proizvodnju trombocita HRP20160404T8 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08305881 2008-12-04
EP09768362.7A EP2352815B1 (en) 2008-12-04 2009-12-04 Method for producing platelets
PCT/EP2009/066401 WO2010063823A1 (en) 2008-12-04 2009-12-04 Method for producing platelets

Publications (2)

Publication Number Publication Date
HRP20160404T1 true HRP20160404T1 (hr) 2016-06-17
HRP20160404T8 HRP20160404T8 (hr) 2016-07-01

Family

ID=40756593

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160404TT HRP20160404T8 (hr) 2008-12-04 2016-04-18 Metoda za proizvodnju trombocita

Country Status (17)

Country Link
US (1) US9012221B2 (hr)
EP (1) EP2352815B1 (hr)
JP (1) JP5863459B2 (hr)
CN (2) CN104087552A (hr)
AU (1) AU2009324042B2 (hr)
BR (1) BRPI0922710A8 (hr)
CA (1) CA2745268C (hr)
CY (1) CY1117452T1 (hr)
DK (1) DK2352815T3 (hr)
ES (1) ES2569610T3 (hr)
HK (1) HK1165491A1 (hr)
HR (1) HRP20160404T8 (hr)
HU (1) HUE027112T2 (hr)
PL (1) PL2352815T3 (hr)
SI (1) SI2352815T1 (hr)
SM (1) SMT201600131B (hr)
WO (1) WO2010063823A1 (hr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012231207B2 (en) 2011-03-18 2016-06-23 New York Blood Center, Inc. Megakaryocyte and platelet production from stem cells
GB201210857D0 (en) 2012-06-19 2012-08-01 Cambridge Entpr Ltd Transcription factor mediated programming towards megakaryocytes
EP3973967A1 (en) 2012-12-21 2022-03-30 Astellas Institute for Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
US9795965B2 (en) 2013-01-03 2017-10-24 Brigham And Women's Hospital, Inc. System and method for a biomimetic fluid processing
US9909102B2 (en) 2013-11-19 2018-03-06 Platod Fluidic device for producing platelets
JP2015181406A (ja) * 2014-03-24 2015-10-22 東レエンジニアリング株式会社 血小板産生装置および血小板産生方法
AU2015241133B2 (en) * 2014-03-31 2019-11-28 Brigham And Women's Hospital, Inc. Systems and methods for biomimetic fluid processing
WO2015179301A1 (en) * 2014-05-19 2015-11-26 Eleftherios Papoutsakis Megakaryocytic particles and microparticles for cell therapy & fate modification of stem and progenitor cells
EP3294871A1 (en) 2015-05-12 2018-03-21 Platod Combination of pharmacological and microfluidic features for improved platelets production
US10947504B2 (en) * 2015-06-16 2021-03-16 Kyoto University Method for producing highly functional platelets
CN108289914B (zh) * 2015-09-08 2022-06-14 布里格姆女子医院有限公司 用于产生血小板的系统和方法
JP6851311B2 (ja) * 2015-09-15 2021-03-31 株式会社メガカリオン 回転式撹拌培養法による血小板の製造方法
WO2017065280A1 (ja) * 2015-10-14 2017-04-20 株式会社メガカリオン 精製血小板の製造方法
EP3372674B1 (en) * 2015-11-02 2020-10-07 Megakaryon Corporation Method for preparing platelets using reciprocating stirring device
US20200123487A1 (en) * 2017-06-20 2020-04-23 Northwestern University Microfluidic platelet bioreactor device and systems
FR3101885A1 (fr) * 2019-10-11 2021-04-16 Etablissement Français Du Sang Systeme pour la liberation de plaquettes et procede de liberation de plaquettes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4344560A (en) * 1979-11-02 1982-08-17 Asahi Kasei Kogyo Kabushiki Kaisha Container, apparatus and method for separating platelets
DE19956156A1 (de) 1999-11-23 2001-06-13 Univ Eberhard Karls Verfahren zur Aufbereitung eines Präparates von Thrombozyten und Thrombozytenpräparat
EP1369128A1 (en) * 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use
AU2005302258B2 (en) * 2004-11-01 2010-10-21 Wisconsin Alumni Research Foundation Platelets from stem cells
PT1836500E (pt) * 2005-01-14 2010-09-28 Ablynx Nv Métodos e ensaios para distinguir diferentes formas de doenças e perturbações caracterizadas por trombocitopenia e/ou por interacção espontânea entre o factor de von willebrand (vwf) e plaquetas
JP5419076B2 (ja) * 2008-05-15 2014-02-19 旭化成メディカル株式会社 血小板の誘導方法

Also Published As

Publication number Publication date
CN102300984B (zh) 2014-06-04
WO2010063823A1 (en) 2010-06-10
CN102300984A (zh) 2011-12-28
CY1117452T1 (el) 2017-04-26
HK1165491A1 (en) 2012-10-05
CA2745268C (en) 2018-11-13
HRP20160404T8 (hr) 2016-07-01
SMT201600131B (it) 2016-07-01
CN104087552A (zh) 2014-10-08
EP2352815A1 (en) 2011-08-10
ES2569610T3 (es) 2016-05-11
DK2352815T3 (en) 2016-05-17
HUE027112T2 (en) 2016-08-29
AU2009324042B2 (en) 2014-12-04
JP5863459B2 (ja) 2016-02-16
AU2009324042A1 (en) 2011-07-07
BRPI0922710A8 (pt) 2018-06-26
JP2012510804A (ja) 2012-05-17
EP2352815B1 (en) 2016-02-10
BRPI0922710A2 (pt) 2016-01-05
PL2352815T3 (pl) 2016-07-29
CA2745268A1 (en) 2010-06-10
US20120014933A1 (en) 2012-01-19
US9012221B2 (en) 2015-04-21
SI2352815T1 (sl) 2016-10-28

Similar Documents

Publication Publication Date Title
HRP20160404T1 (hr) Metoda za proizvodnju trombocita
Parnia et al. Overview of nanoparticle coating of dental implants for enhanced osseointegration and antimicrobial purposes
Sims et al. Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption
Wang et al. Self-assembled peptide nanofibers on graphene oxide as a novel nanohybrid for biomimetic mineralization of hydroxyapatite
Klein-Nulend et al. Mechanosensation and transduction in osteocytes
Reinholt et al. Osteopontin--a possible anchor of osteoclasts to bone.
Yang et al. Autophagy in SDF-1α-mediated DPSC migration and pulp regeneration
JP2010520788A5 (hr)
PE20060872A1 (es) Colorantes de cianina en el diagnostico de enfermedades proliferativas
Nie et al. Effect of magnesium ions/Type I collagen promote the biological behavior of osteoblasts and its mechanism
DK1268435T3 (da) 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk aktivitet
EA200800971A1 (ru) Фармацевтические композиции модулятора 5-нтрецепторов серотонина, полезные в лечении связанных с ними нарушений
BRPI0515505A (pt) derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase
GT200600174A (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion
Alfarsi et al. Titanium surface hydrophilicity enhances platelet activation
Wang et al. Hydroxyapatite-coated titanium by micro-arc oxidation and steam–hydrothermal treatment promotes osseointegration
Zeng et al. The osteoimmunomodulatory properties of MBG scaffold coated with amino functional groups
AR032499A1 (es) Composiciones
He et al. Cu and Si co-doped microporous TiO2 coating for osseointegration by the coordinated stimulus action
Yang et al. TiO2 nanotubes alleviate diabetes-induced osteogenetic inhibition
EP2074100A1 (de) Biofilm-hemmende wirkung sowie anti-infektive aktivität n,c-verknüpfter arylisochinoline und deren verwendung
PE20050245A1 (es) Antagonistas de nmda/nr2b nonaril - heterociclicos n-sustituidos
Marcatti Amarú Maximiano et al. Nanotextured titanium surfaces stimulate spreading, migration, and growth of rat mast cells
RS52073B (en) PLANTS WITH IMPROVED GROWTH ABILITY AND RESISTANCE TO DISEASES AND THE METHOD OF PRODUCTION
Farley Ultrastructure of book gill development in embryos and first instars of the horseshoe crab Limulus polyphemus L.(Chelicerata, Xiphosura)